Case 1: Relapsed DLBCL, Transplant Eligible
Clinical Cases in Relapsed and Refractory DLBCL
Experts review clinical cases and best practices for managing relapsed/refractory DLBCL.
L-MIND and RE-MIND Practical Implications
RE-MIND Comparison Data Review
Phase 2 L-MIND Trial Overview
Targeting CD19 in Diffuse Large B-Cell Lymphoma: Treatment Updates
A key opinion leader provides an overview of emerging data for a promising CD-19 targeted therapy and discusses how it has impacted the treatment paradigm.
Case 3: Distant Metastases in Triple-Positive Breast Cancer
Case 3: Triple-Positive Metastatic Breast Cancer
Case 2: Novel Agents in Late-Stage Clinical Trials for HER2+ MBC
Case 2: Sequencing Treatments for HER2+ Breast Cancer
Case 2: Adverse Effects of Treatments for HER2+ Breast Cancer
Case 2: Risk Factors for Brain Metastases in HER2+ Breast Cancer
Case 2: Impact of Brain Metastases in HER2+ Breast Cancer
Case 2: Later-Line Treatment of HER2+ Breast Cancer
Case 2: Previously Treated HER2+ Breast Cancer
Case 2: Relapsed/Refractory HR-/HER2+ Breast Cancer
Case 1: Subcutaneous Trastuzumab-Pertuzumab for HER2+ Breast Cancer
Case 1: De-Escalation of Adjuvant Anti-HER2 Therapy for Breast Cancer
Case 1: Adjuvant Trials for HER2+ Breast Cancer
Case 1: Adjuvant Therapy After pCR in Early Stage HER2+ Breast Cancer
Case 1: Adjuvant Treatment for Residual Disease in Early Stage HER2+ Breast Cancer
Case 1: Choosing Therapy for Early Stage HER2+ Breast Cancer
Case 1: Neoadjuvant Therapy for Early-Stage HER2+ Breast Cancer
Case 1: Molecular Testing for HER2+ Breast Cancer
Case 1: Early Stage HER2+ Breast Cancer
Clinical Cases in HER2+ Breast Cancer
Experts in breast oncology review 3 clinical cases of HER2+ breast cancer and discuss individualized treatment approaches for each patient.
Case 3: Management of Immune-Related Toxicities in Stage III NSCLC
Case 3: Standard of Care in Unresectable Stage III NSCLC
Case 3: PACIFIC Trial in Unresectable Stage III NSCLC
Case 3: Chemoradiation for Stage III NSCLC